Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
28 June 2018Website:
http://www.enterabio.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 01 Nov 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ENTX Latest News
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences:
Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.
Entera Bio Ltd. (ENTX) closed at $1.98 on the most recent trading day, reflecting a 1% decrease from the previous closing price.
At the end of the most recent trading day, Entera Bio Ltd. (ENTX) closed at $2.24, reflecting a 0.9% increase from the previous day's closing price.
Here is the performance comparison of Entera Bio Ltd. (ENTX) and FibroGen (FGEN) relative to their sector year to date.
In this article, we explore why purchasing Entera Bio (ENTX) stock at this time could be a wise decision.
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12.
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.
What type of business is Entera Bio?
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
What sector is Entera Bio in?
Entera Bio is in the Healthcare sector
What industry is Entera Bio in?
Entera Bio is in the Biotechnology industry
What country is Entera Bio from?
Entera Bio is headquartered in Israel
When did Entera Bio go public?
Entera Bio initial public offering (IPO) was on 28 June 2018
What is Entera Bio website?
https://www.enterabio.com
Is Entera Bio in the S&P 500?
No, Entera Bio is not included in the S&P 500 index
Is Entera Bio in the NASDAQ 100?
No, Entera Bio is not included in the NASDAQ 100 index
Is Entera Bio in the Dow Jones?
No, Entera Bio is not included in the Dow Jones index
When was Entera Bio the previous earnings report?
No data
When does Entera Bio earnings report?
The next expected earnings date for Entera Bio is 14 November 2024